TABLE 1

The ln2 quantitative iTRAQ values of APPs from day 7

Drug/ControlLPS/Control[LPS Plus Drug]/LPSProtein
1.43.0−1.2Transferrin
1.14.2−1.9α1-antitrypsin
1.04.2−2.0α1 antiproteinase
0.53.8−1.3Haptoglobin
3.43.90.1Serum albumin
3.43.90.1Hypothetical protein
−0.82.1−1.0Vitamin D binding protein
1.23.8−0.9Ceruloplasmin
1.72.40.0Liver carboxylesterase 1 isoform a
2.33.7−1.2Angiotensinogen
3.67.0−1.3α1-acid glycoprotein 1
−1.65.0−1.5α1-acid glycoprotein 2
0.31.5−1.0α2-HS glycoprotein
−1.03.3−2.0α2 macroglobulin
2.75.0−1.9Retinol binding protein 4
1.85.1−1.7Complement component C3
1.21.3−0.9Transthyretin
1.52.8−0.5Leucine-rich α2-glycoprotein
2.3−1.78.5Amyloid β A4 protein isoform b
  • The drug- and LPS-treated samples were normalized to untreated samples (control). The LPS and LPS and drug treatment samples were normalized to LPS samples. As the values indicate, the treatment of drug (440 μM DCF) suppressed the synthesis of APPs.